总部位于加利福尼亚的临床阶段生物技术公司（OTCQB：ISCO）国际干细胞公司（ISCO）（ISCO）宣布开发一种新的3D生物生产者，该新3D生物生产者生产肝组织。
该技术适合肝脏祖细胞（LPC）系列，增加了ISCO现有的产品管道，包括用于脑部治疗的ISC-HPNSC，以及用于治疗骨关节炎的软骨。
ISC-HPNSC用于帕金森氏病的治疗用途是在I期临床踪迹中，这使其成为ISCO最接近市场的线路。相比之下，肝细胞仍处于基础研究阶段，这意味着3D生物打印可能对进展非常宝贵。
从第一个真正的干细胞库
The LPCs used in ISCO’s liver 3D bioprinter are generated by the firm’s proprietary parthenogenesis technology – a process ISCO is using to build what it calls “the first true stem cell bank, UniStemCell™.”
单性生殖成分从未施用的卵细胞中创建了干细胞样本，绕过了围绕可行人类胚胎细胞使用的伦理问题。此外，产生的细胞没有任何可以从其他方法中获得的遗传疾病，而且从ISCO的产品管道中可以明显看出，可以发展成各种细胞类型，以在体内广泛使用。
罗素·克恩（Russell Kern），，，，Executive Vice President and Chief Scientific Officer of ISCO, comments, “We have already developed a master cell bank of the liver progenitor cells and, we are proceeding to test safety and efficacy of the cells in various models of liver diseases like liver cirrhosis and fibrosis.”
治疗，药物和筛查
In a statement on the announcement Kern also detailed some of the potential applications for the firm’s new 3D liver technology, citing an ability “to replace damaged tissue to restore liver functions,” and use “in drug discovery as a model for drug screening,” i.e.芯片设备的器官。
In this relatively young market developing technology for a specific purpose, such as 3D bioprinting the liver, could be key to ISCO’s success as many machines on the market run the risk of spreading their possibilities too thinly.
Revotek is one example of another company specializing in 3D bioprinting for specific organic structures. In a project funded by the Chinese government,the Revotek-T series blood vessel 3D bioprinter做了一个静脉部分successfully implanted into the abdomens of 30 macaque monkeys.
For more of the latest medical 3D bioprinting news,sign up to the 3D Printing Industry newsletter，，，，在推特上关注我们andlike us on Facebook。Register on our 3D printing jobs site here.
特色图像显示了国际干细胞公司首页的“研究和治疗细胞”口号。图片通过国际干细胞公司
